BEFUNOLOL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H21NO4.ClH
Molecular Weight	327.803
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O

InChI

InChIKey=TVVTWOGRPVJKDJ-UHFFFAOYSA-N

InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H21NO4
Molecular Weight	291.3422
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14977495

Befunolol is a beta-adrenergic receptor blocker approved in Japan for the treatment of open-angle glaucoma. The current drug status is unknown.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11163052	Antagonist 2849		8.97 null [pKd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Open-angle glaucoma 53 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11163052	Primary		Approved 8583	BENTOS Approved Use Unknown

Doses

Dose	Population	Adverse events
1 % 1 times / day multiple, ophthalmic Dose: 1 %, 1 times / day Route: ophthalmic Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2906845/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2906845/	Disc. AE: Contact dematitis... AEs leading to discontinuation/dose reduction: Contact dematitis (6 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/2906845/

AEs

AE	Significance	Dose	Population
Contact dematitis	6 patients Disc. AE	1 % 1 times / day multiple, ophthalmic Dose: 1 %, 1 times / day Route: ophthalmic Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2906845/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2906845/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	AKR1C1 22 AKR1C2 12 carbonyl reductase 3

Drug as victim

Target	Modality	Activity
AKR1C1 22	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18949601/	yes [Km 520 uM]
AKR1C2 12	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18949601/	yes [Km 760 uM]
carbonyl reductase 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27298339/	yes

PubMed

Title	Date	PubMed
Reconstruction of a human cornea by the self-assembly approach of tissue engineering using the three native cell types.	2010-10-29	21139684
Pharmacological evaluation of ocular beta-adrenoceptors in rabbit by tissue segment binding method.	2009-01-30	19087880
Allergic contact dermatitis due to levobunolol with cross-sensitivity to befunolol.	2007-01	17177718
Utilization of 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) for kinetic spectrophotometric assay of befunolol hydrochloride in its pharmaceutical formulation.	2006-06-24	16792064
Human cornea construct HCC-an alternative for in vitro permeation studies? A comparison with human donor corneas.	2005-07	15939241
Human corneal equivalent as cell culture model for in vitro drug permeation studies.	2004-04	15031177
[Levels of antiphospholipid antibodies in the serum and aqueous humor of glaucoma patients].	2004	15636221
The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride.	2003-01-02	12480285
Contact dermatitis to topical drugs for glaucoma.	2001-12	11753897
Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists.	2001-06	11436944
Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol.	2001-06	11380552
Aqueous humor dynamics in beagle dogs with caffeine-induced ocular hypertension.	1998-06	9673947
Relationship between caffeine-induced ocular hypertension and ultrastructure changes of non-pigmented ciliary epithelial cells in rats.	1997-12	9442454

Patents

Sample Use Guides

In Vivo Use Guide

1% solution 2 times daily.

Route of Administration: Other

In Vitro Use Guide

Human cornea construct was used to test befunolol (0,5%) permeability.The permeation coefficient was 9,88*10(-6) cm/s.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:42:16 GMT 2025` Edited by `admin` on `Mon Mar 31 18:42:16 GMT 2025`
Record UNII	B03Z2VY37I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEFUNOLOL HYDROCHLORIDE

Common Name

English

BFE-60

Preferred Name

English

BEFUNOLOL HYDROCHLORIDE [JAN]

Common Name

English

BEFUNOLOL HYDROCHLORIDE [MART.]

Common Name

English

1-(7-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-2-BENZOFURANYL)ETHANONE HYDROCHLORIDE

Systematic Name

English

2-ACETYL-7-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)BENZOFURAN HYDROCHLORIDE

Systematic Name

English

Befunolol hydrochloride [WHO-DD]

Common Name

English

BEFUNOLOL HYDROCHLORIDE [MI]

Common Name

English

BEFUNOLOL HCL

Common Name

English

Code System Code Type Description

EVMPD

SUB00686MIG